{"id":53799,"date":"2026-01-12T22:12:59","date_gmt":"2026-01-12T14:12:59","guid":{"rendered":"https:\/\/flcube.com\/?p=53799"},"modified":"2026-01-12T22:13:13","modified_gmt":"2026-01-12T14:13:13","slug":"mirxes-partners-with-thailands-n-health-to-launch-mirna-cancer-screening","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53799","title":{"rendered":"Mirxes Partners with Thailand&#8217;s N Health to Launch miRNA Cancer Screening"},"content":{"rendered":"\n<p><strong>Mirxes Holding Company Ltd<\/strong>, a Singapore\u2011headquartered RNA technology company, announced a strategic partnership with <strong>N Health<\/strong>, a healthcare solutions provider and member of <strong>Bangkok Dusit Medical Services (BDMS) Group<\/strong>, to introduce advanced <strong>microRNA (miRNA) cancer screening solutions<\/strong> to Thailand. The collaboration will deploy Mirxes&#8217; <strong>GASTROClear<\/strong> (gastric cancer) and <strong>LUNGClear<\/strong> (lung cancer) tests across <strong>nearly 60 hospitals<\/strong> in the N Health network, creating a scalable model for early disease detection in Thailand and Southeast Asia.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-overview\">Partnership Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Mirxes Holding Company Ltd, N Health (BDMS Group member)<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>microRNA (miRNA) cancer screening<\/td><\/tr><tr><td><strong>Products<\/strong><\/td><td>GASTROClear (gastric cancer), LUNGClear (lung cancer)<\/td><\/tr><tr><td><strong>Market<\/strong><\/td><td>Thailand (initial), Southeast Asia (expansion)<\/td><\/tr><tr><td><strong>Network Reach<\/strong><\/td><td>~60 hospitals within N Health network<\/td><\/tr><tr><td><strong>Strategic Goal<\/strong><\/td><td>Scalable early cancer detection model<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-mirna-screening\">Technology Profile: miRNA Screening<\/h2>\n\n\n\n<p><strong>Mechanism<\/strong>: Mirxes&#8217; platform detects <strong>circulating microRNA biomarkers<\/strong> in blood, enabling <strong>non\u2011invasive, high\u2011sensitivity<\/strong> detection of gastric and lung cancers at early stages when treatment outcomes are significantly improved.<\/p>\n\n\n\n<p><strong>GASTROClear<\/strong>: Validated for <strong>gastric cancer screening<\/strong> with <strong>&gt;85% sensitivity<\/strong> and <strong>specificity<\/strong>, addressing Asia\u2019s highest gastric cancer incidence region.<\/p>\n\n\n\n<p><strong>LUNGClear<\/strong>: Targets <strong>lung cancer<\/strong> detection, critical for Thailand\u2019s <strong>smoking\u2011related cancer burden<\/strong> and <strong>air pollution exposure risks<\/strong>.<\/p>\n\n\n\n<p><strong>Market Significance<\/strong>: <strong>First miRNA\u2011based cancer screening platform<\/strong> entering Thailand\u2019s healthcare system, offering <strong>cost\u2011effective alternative<\/strong> to endoscopy and CT imaging for high\u2011risk populations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<p><strong>Thailand Cancer Burden<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Gastric Cancer Incidence<\/strong>: <strong>~10,000<\/strong> new cases annually, <strong>50%<\/strong> diagnosed at late stage<\/li>\n\n\n\n<li><strong>Lung Cancer Incidence<\/strong>: <strong>~25,000<\/strong> new cases annually, <strong>70%<\/strong> present at advanced stage<\/li>\n\n\n\n<li><strong>Screening Gap<\/strong>: <strong>&lt;20%<\/strong> of high\u2011risk individuals undergo regular screening due to <strong>cost and access barriers<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Market Size<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Thailand Cancer Screening Market<\/strong>: <strong>\u00a53\u20114\u202fbillion<\/strong> (US$420\u2011560\u202fmillion) in 2025, growing at <strong>12% CAGR<\/strong><\/li>\n\n\n\n<li><strong>miRNA Sub\u2011segment<\/strong>: <strong>\u00a5500\u2011800\u202fmillion<\/strong> opportunity by 2030<\/li>\n\n\n\n<li><strong>Southeast Asia Expansion<\/strong>: <strong>\u00a52\u20113\u202fbillion<\/strong> additional market potential across <strong>Indonesia, Malaysia, Vietnam<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>BDMS Network Advantage<\/strong>: <strong>N Health\u2019s 60\u2011hospital network<\/strong> provides immediate <strong>market access<\/strong> to <strong>urban and regional centers<\/strong>, accelerating <strong>adoption and reimbursement pathways<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications\">Financial Implications<\/h2>\n\n\n\n<p><strong>Revenue Model<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Test Pricing<\/strong>: Projected <strong>\u00a51,500\u20112,000<\/strong> per miRNA test (vs. <strong>\u00a55,000\u20118,000<\/strong> for endoscopy\/CT)<\/li>\n\n\n\n<li><strong>Volume Trajectory<\/strong>: <strong>100,000\u2011150,000<\/strong> tests annually by 2027, scaling to <strong>500,000<\/strong> by 2030<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong>: <strong>\u00a5150\u2011300\u202fmillion<\/strong> (US$21\u201142\u202fmillion) for Mirxes by 2028<\/li>\n<\/ul>\n\n\n\n<p><strong>Partnership Economics<\/strong>: <strong>Revenue\u2011sharing model<\/strong> with N Health likely <strong>60\/40<\/strong> (Mirxes\/N Health), given <strong>technology ownership vs. distribution network<\/strong>.<\/p>\n\n\n\n<p><strong>Platform Validation<\/strong>: Thailand partnership <strong>de\u2011risks<\/strong> Mirxes\u2019 <strong>global expansion strategy<\/strong>, following <strong>successful launches in Singapore and Japan<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Mirxes\u2019 market penetration, revenue forecasts, and partnership expansion in Southeast Asia. Actual results may differ materially due to regulatory approvals, reimbursement negotiations, competitive responses, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mirxes Holding Company Ltd, a Singapore\u2011headquartered RNA technology company, announced a strategic partnership with N&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[811],"class_list":["post-53799","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-mirxes"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mirxes Partners with Thailand&#039;s N Health to Launch miRNA Cancer Screening - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Mirxes Holding Company Ltd, a Singapore\u2011headquartered RNA technology company, announced a strategic partnership with N Health, a healthcare solutions provider and member of Bangkok Dusit Medical Services (BDMS) Group, to introduce advanced microRNA (miRNA) cancer screening solutions to Thailand. The collaboration will deploy Mirxes&#039; GASTROClear (gastric cancer) and LUNGClear (lung cancer) tests across nearly 60 hospitals in the N Health network, creating a scalable model for early disease detection in Thailand and Southeast Asia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53799\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mirxes Partners with Thailand&#039;s N Health to Launch miRNA Cancer Screening\" \/>\n<meta property=\"og:description\" content=\"Mirxes Holding Company Ltd, a Singapore\u2011headquartered RNA technology company, announced a strategic partnership with N Health, a healthcare solutions provider and member of Bangkok Dusit Medical Services (BDMS) Group, to introduce advanced microRNA (miRNA) cancer screening solutions to Thailand. The collaboration will deploy Mirxes&#039; GASTROClear (gastric cancer) and LUNGClear (lung cancer) tests across nearly 60 hospitals in the N Health network, creating a scalable model for early disease detection in Thailand and Southeast Asia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53799\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-12T14:12:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-12T14:13:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53799#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53799\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mirxes Partners with Thailand&#8217;s N Health to Launch miRNA Cancer Screening\",\"datePublished\":\"2026-01-12T14:12:59+00:00\",\"dateModified\":\"2026-01-12T14:13:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53799\"},\"wordCount\":428,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Mirxes\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53799#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53799\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53799\",\"name\":\"Mirxes Partners with Thailand's N Health to Launch miRNA Cancer Screening - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-12T14:12:59+00:00\",\"dateModified\":\"2026-01-12T14:13:13+00:00\",\"description\":\"Mirxes Holding Company Ltd, a Singapore\u2011headquartered RNA technology company, announced a strategic partnership with N Health, a healthcare solutions provider and member of Bangkok Dusit Medical Services (BDMS) Group, to introduce advanced microRNA (miRNA) cancer screening solutions to Thailand. The collaboration will deploy Mirxes' GASTROClear (gastric cancer) and LUNGClear (lung cancer) tests across nearly 60 hospitals in the N Health network, creating a scalable model for early disease detection in Thailand and Southeast Asia.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53799#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53799\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53799#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mirxes Partners with Thailand&#8217;s N Health to Launch miRNA Cancer Screening\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mirxes Partners with Thailand's N Health to Launch miRNA Cancer Screening - Insight, China&#039;s Pharmaceutical Industry","description":"Mirxes Holding Company Ltd, a Singapore\u2011headquartered RNA technology company, announced a strategic partnership with N Health, a healthcare solutions provider and member of Bangkok Dusit Medical Services (BDMS) Group, to introduce advanced microRNA (miRNA) cancer screening solutions to Thailand. The collaboration will deploy Mirxes' GASTROClear (gastric cancer) and LUNGClear (lung cancer) tests across nearly 60 hospitals in the N Health network, creating a scalable model for early disease detection in Thailand and Southeast Asia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53799","og_locale":"en_US","og_type":"article","og_title":"Mirxes Partners with Thailand's N Health to Launch miRNA Cancer Screening","og_description":"Mirxes Holding Company Ltd, a Singapore\u2011headquartered RNA technology company, announced a strategic partnership with N Health, a healthcare solutions provider and member of Bangkok Dusit Medical Services (BDMS) Group, to introduce advanced microRNA (miRNA) cancer screening solutions to Thailand. The collaboration will deploy Mirxes' GASTROClear (gastric cancer) and LUNGClear (lung cancer) tests across nearly 60 hospitals in the N Health network, creating a scalable model for early disease detection in Thailand and Southeast Asia.","og_url":"https:\/\/flcube.com\/?p=53799","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-12T14:12:59+00:00","article_modified_time":"2026-01-12T14:13:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53799#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53799"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mirxes Partners with Thailand&#8217;s N Health to Launch miRNA Cancer Screening","datePublished":"2026-01-12T14:12:59+00:00","dateModified":"2026-01-12T14:13:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53799"},"wordCount":428,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Mirxes"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53799#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53799","url":"https:\/\/flcube.com\/?p=53799","name":"Mirxes Partners with Thailand's N Health to Launch miRNA Cancer Screening - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-12T14:12:59+00:00","dateModified":"2026-01-12T14:13:13+00:00","description":"Mirxes Holding Company Ltd, a Singapore\u2011headquartered RNA technology company, announced a strategic partnership with N Health, a healthcare solutions provider and member of Bangkok Dusit Medical Services (BDMS) Group, to introduce advanced microRNA (miRNA) cancer screening solutions to Thailand. The collaboration will deploy Mirxes' GASTROClear (gastric cancer) and LUNGClear (lung cancer) tests across nearly 60 hospitals in the N Health network, creating a scalable model for early disease detection in Thailand and Southeast Asia.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53799#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53799"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53799#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mirxes Partners with Thailand&#8217;s N Health to Launch miRNA Cancer Screening"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53799"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53799\/revisions"}],"predecessor-version":[{"id":53800,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53799\/revisions\/53800"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}